8th April 2025
SYMBYX Biome is proud to announce its selection by Newcastle University in the UK to support a major clinical trial testing the effects of light therapy (also known as photobiomodulation) on Parkinson’s symptoms.
Led by Professor Nicola Pavese, a leading neurologist and movement disorder expert at the Clinical Ageing Research Unit (CARU) in Newcastle upon Tyne, the study will involve more than 80 participants receiving treatment over six months. SYMBYX will supply its medical-grade laser devices and help design the treatment protocols. In addition to tracking improvements in both motor and non-motor symptoms (such as tremors, balance, sleep, and mood), researchers will also analyse motor fluctuations and collect gut microbiome samples from each participant. The gut-brain axis is increasingly considered an important transmission pathway, especially in body first Parkinson’s.
Parkinson’s disease (PD) is the world’s fastest-growing neurodegenerative condition, affecting over 12 million people. It’s a progressive condition, with many of the symptoms caused by a reduction in dopamine levels – an essential brain chemical that helps control movement, mood, and motivation. While Parkinson’s is often recognised by movement-related symptoms like tremor and muscle stiffness, many people also experience non-motor symptoms such as digestive problems, sleep issues, loss of smell, depression, and anxiety—often years before diagnosis.
Previous small-scale studies have shown that SYMBYX light therapy, particularly when used on the gut, may help ease both motor and non-motor symptoms in people with Parkinson’s. This new trial aims to build on those findings with a larger group of participants, helping to validate the therapy’s benefits and potential for broader use.
Dr Wayne Markman, CEO of SYMBYX, said: “We’re honoured to work with Newcastle University, a leader in Parkinson’s research and care. Their expertise and dedication make them an ideal partner. Light therapy is showing real promise in improving quality of life for people with Parkinson’s, and we’re excited to be part of this important study.”
Participant recruitment is expected to begin in mid-2025, with results expected in late 2026.
About SYMBYX
SYMBYX Biome is a MedTech company helping people improve their health using targeted light therapy. With a strong focus on customers and science, SYMBYX partners with global experts to create evidence-based, next-generation light therapy devices. SYMBYX medical lasers are approved in the UK for easing symptoms of Parkinson’s.
Media Contact
For interviews with Dr Wayne Markman or further information:
Email: marketing@symbyxbiome.com
Phone: +61 8066 9966
